ArticleJournal of family medicine and primary care2019
Using caffeine on the patients as therapeutic option against treatment-resistant obsessive-compulsive disorder.
Article in Journal of family medicine and primary care, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 8 citations in OpenAlex.
- Nutraceuticals and obsessive-compulsive disorder therapy.Advances in neurotoxicology · 2026Article
- Article
- Association Between Coffee Intake and Common Mental Disorders: Insights From Genetic Analysis.CNS neuroscience & therapeutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionObsessive-compulsive disorder (OCD) is one of the most common and debilitating diseases. Approximately 40-30% of these patients are resistant to treatment, which auxiliary drugs are used to treat these patients. One of these drugs is caffeine, which is capable of affecting adenosine receptors and interfering with its release and serotonin reuptake. Considering the limitations of previous studies in this area, including lack of control group, this double-blind study compared the effectiveness of caffeine in the management of patients with treatment-resistant OCD in comparison with placebo group. MATERIALS AND
methods62 patients who referred to the psychiatric clinic of Imam Hossein Hospital in Tehran from 2017 to 2018 were enrolled in the study. According to the psychiatrist's interview, patients with OCD were selected randomly in two groups including caffeine and placebo, after having met the criteria for inclusion and obtaining informed consent. Patients were followed for 8 weeks and compared in terms of the severity of OCD before and after intervention using YBOCS questionnaire.
resultsThe two groups of treatment and control were similar in terms of study variables (gender, age, education, age, comorbidity). The mean Yale-Brown Obsessive Compulsive Scale (Y-BOCS) in the treatment and control groups before intervention were determined to be 27.16 and 25.4, respectively, which changed to 24 and 27.23 after medication intervention, which exhibited a decrease of about 3 points (12%) in the treatment group, and was statistically significant based on linear regression analysis (
conclusionBased on the findings of our study, caffeine can reduce the severity of the symptoms of OCD and serve as an auxiliary treatment for OCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.